N-acetyl-cysteine exhibits potent anti-mycobacterial activity in addition to its known anti-oxidative functions

Abstract

Background Mycobacterium tuberculosis infection is thought to induce oxidative stress. N-acetyl-cysteine (NAC) is widely used in patients with chronic pulmonary diseases including tuberculosis due to its mucolytic and anti-oxidant activities. Here, we tested whether NAC exerts a direct antibiotic activity against mycobacteria.MethodsOxidative stress status in plasma was compared between pulmonary TB (PTB) patients and those with latent M. tuberculosis infection (LTBI) or healthy uninfected individuals. Lipid peroxidation, DNA oxidation and cell death, as well as accumulation of reactive oxygen species (ROS) were measured in cultures of primary human monocyte-derived macrophages infected with M. tuberculosis and treated or not with NAC. M. tuberculosis, M. avium and M. bovis BCG cultures were also exposed to different doses of NAC with or without medium pH adjustment to control for acidity. The anti-mycobacterial effect of NAC was assessed in M. tuberculosis infected human THP-1 cells and bone marrow-derived macrophages from mice lacking a fully functional NADPH oxidase system. The capacity of NAC to control M. tuberculosis infection was further tested in vivo in a mouse (C57BL/6) model.ResultsPTB patients exhibited elevated levels of oxidation products and a reduction of anti-oxidants compared with LTBI cases or uninfected controls. NAC treatment in M. tuberculosis-infected human macrophages resulted in a decrease of oxidative stress and cell death evoked by mycobacteria. Importantly, we observed a dose-dependent reduction in metabolic activity and in vitro growth of NAC treated M. tuberculosis, M. avium and M. bovis BCG. Furthermore, anti-mycobacterial activity in infected macrophages was shown to be independent of the effects of NAC on the host NADPH oxidase system in vitro. Short-term NAC treatment of M. tuberculosis infected mice in vivo resulted in a significant reduction of mycobacterial loads in the lungs.ConclusionsNAC exhibits potent anti-mycobacterial effects and may limit M. tuberculosis infection and disease both through suppression of the host oxidative response and through direct antimicrobial activity.Electronic supplementary materialThe online version of this article (doi:10.1186/s12866-016-0872-7) contains supplementary material, which is available to authorized users.

Inhibition of Transglutaminase 2 as a Potential Host-Directed Therapy Against Mycobacterium tuberculosis

“…In these experiments, L-cysteine or NAC where administered at a concentration of 4 mM, which is five times higher than the concentration we used in our experiments involving Mtb-infected macrophages. Indeed NAC administered at a concentration of 10 mM was shown to directly decrease Mtb replication (42). However, in this study, we show a reproduction of the experimental conditions indicated in Vilcheze et al (20), wherein cystamine or cysteamine, when administered at the concentrations used in Mtb-infected macrophages (400 and 800 µM, respectively), did not exert any direct activity against Mtb cultured in axenic media and did not prevent the emergence of drug tolerance against isoniazid.…”

The Role of N-Acetyl Sistein in Pulmonary Tuberculosis

“…Previous studies have suggested that active TB patients have an association with excessive oxidative stress with a decrease in antioxidant concentration and increased free radicals. 5,9 The oxidative environment normally helps to kill pathogenic microorganisms. However, in the intracellular pathogen of MTB, the opposite can grow well in macrophages in environments with high oxygen concentrations.…”

“…4 MTB infection can induce oxidative stress. 5 Oxidative stress results from an imbalance between reactive oxygen species (ROS) and antioxidants. Cells have several endogenous antioxidants as defense mechanisms, they are vitamin C, vitamin E and SOD enzymes, catalase, glutathione peroxidase, and endogenous thiol.…”

Genetic polymorphism of glutathione s-transferase M1 (GSTM1) in patients with susceptible and resistant tuberculosis

“…According to World Health Organization (WHO), anti-TB drugs are classified into five groups, based on evidence of efficacy, potency and drug class. In the frame of actual used DOTS (Directly Observed Treatment Short Course Chemotherapy) strategy 1,2 , the anti-tuberculosis (TB) treatment is standardized, meaning that all patients receive the same regimens, being included in well-defined groups. The standard treatment has advantages over individualized treatment by preventing prescription errors, appropriate appreciation of drug needs, distribution and monitoring 3,4 .…”